107 completed. 107 Phase 2, 19 Phase 1, 15 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 107 | Completed 107 |
| Phase 1 | 19 | Completed 19 |
| Phase 3 | 15 | Completed 15 |
Follow Apnea: new trials by email Literature Review of Apnea trials Research Report on Apnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension Lorundrostat, Placebo - Obstructive Sleep Apnea, Hypertension | Phase 2 | Completed | Mineralys Therapeutics Inc. | 48 | 2025-02-28 | 2026-08-21 |
| Study That Tests AD109 in Patients Taking GLP-1 Drugs AD109 - OSA | Phase 2 | Completed | Apnimed | 40 | 2024-05-20 | 2025-02-19 |
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA IHL-42X Low Dose, IHL-42X High Dose, Placebo - Obstructive Sleep Apnea | Phase 2 / Phase 3 | Completed | Incannex Healthcare Ltd | 121 | 2024-05-02 | 2026-07-27 |
| Managing Opioid Related Sleep Apnea With Acetazolamide Acetazolamide, Placebo - Sleep-Disordered Breathing, Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 39 | 2023-10-18 | 2026-03-10 |
| Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP) Eszopiclone 2 mg, Placebo - Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 42 | 2023-08-31 | 2025-11-25 |
| AD816 Crossover Study Period A, Period B, Period C - OSA, Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 25 | 2023-04-28 | 2023-11-15 |
| Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1, Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2, Placebo Day 1 - OSA | Phase 1 / Phase 2 | Completed | Chulalongkorn University | 10 | 2023-02-01 | 2025-09-17 |
| Acetazolamide on REM OSA Placebo oral capsule, Acetazolamide - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 11 | 2023-01-30 | 2026-01-20 |
| Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health Acetazolamide, Placebo, Continuous Positive Airway Pressure - Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 54 | 2022-12-02 | 2025-11-25 |
| Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome AD981, Placebo - Obesity Hypoventilation Syndrome (OHS) | Phase 2 | Completed | Istituto Auxologico Italiano | 15 | 2022-06-21 | 2025-02-27 |
| Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea Quetiapine 50 MG, Placebo - Sleep Apnea, Obstructive | Phase 2 | Completed | Flinders University | 15 | 2022-05-25 | 2023-07-06 |
| Pediatric Pain Optimization After Tonsillectomy Fentanyl/Hydromorphone, Methadone - Obstructive Sleep Apnea, Tonsillitis | Phase 2 | Completed | Duke University | 66 | 2022-04-08 | 2024-10-17 |
| Parallel Arm Trial of AD109 and AD504 In Patients With OSA AD109, AD504, Atomoxetine Hydrochloride - OSA - Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 294 | 2021-11-29 | 2026-08-12 |
| Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA) Sulthiame - Obstructive Sleep Apnea | Phase 2 | Completed | Desitin Arzneimittel GmbH | 298 | 2021-11-23 | 2023-11-29 |
| Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) Dosing 1: Atomoxetine, AD313 - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Apnimed | 15 | 2021-10-19 | 2023-04-07 |
| Prospective Randomized Trial of CPAP for SDB in Patients Who Use Opioids Positive Airway Pressure (PAP) - Sleep Disorder; Breathing-Related, Pain | Phase 2 | Completed | University of California, San Diego | 62 | 2021-08-10 | 2024-12-02 |
| Trial of AD113 and Atomoxetine in OSA Patients With Hypertension AD113, Atomoxetine - Obstructive Sleep Apnea, Hypertension | Phase 2 | Completed | Apnimed | 21 | 2021-07-31 | 2023-08-21 |
| A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea BAY2586116, Placebo - Sleep Apnea, Obstructive | Phase 2 | Completed | Bayer | 93 | 2021-03-03 | 2022-10-26 |
| AD109 Dose Finding in Mild to Moderate OSA AD109 dose1- A, AD109 dose2- B, Placebo- C - Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 32 | 2020-12-22 | 2022-12-22 |
| Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing AD036, Placebo - Sleep Disordered Breathing | Phase 2 | Completed | Brigham and Women's Hospital | 53 | 2020-12-02 | 2022-03-02 |
Showing 20 of 107. Sign in to see all of them.
Sleep Apnea, Obstructive (75) · Sleep Apnea Syndromes (45) · Hypertension (10) · Obesity (6) · Sleep Wake Disorders (6) · Sleep Apnea, Central (4) · Stroke (4) · Diabetes Mellitus (3) · Pain (3) · Sleep Initiation and Maintenance Disorders (3) · Cardiovascular Diseases (2) · Chronic Pain (2) · Disorders of Excessive Somnolence (2) · Ischemic Attack, Transient (2)
Respiratory Tract Diseases (107) · Respiration Disorders (105) · Dyssomnias (104) · Nervous System Diseases (104) · Sleep Disorders, Intrinsic (104) · Sleep Wake Disorders (98) · Sleep Apnea Syndromes (59) · Pathological Conditions, Signs and Symptoms (26) · Signs and Symptoms (23) · Vascular Diseases (15) · Cardiovascular Diseases (14) · Neurologic Manifestations (11) · Mental Disorders (10) · Nutritional and Metabolic Diseases (10)
Continuous Positive Airway Pressure (12) · Atomoxetine Hydrochloride (8) · Acetazolamide (6) · Eszopiclone (4) · oxybutynin (3) · Desipramine (2) · Dronabinol (2) · Occlusal Splints (2) · Oxygen (2) · (Lys-Gly)(5)cyclo(75-82)MBP(74-85) (1) · 4-Aminopyridine (1) · Adrenergic beta-Antagonists (1) · Allopurinol (1) · Analgesics, Opioid (1) · Atorvastatin (1)
Brigham and Women's Hospital (15) · Apnimed (10) · University of California, San Diego (6) · VA Office of Research and Development (6) · Johns Hopkins University (4) · Bayer (3) · Apnex Medical, Inc. (2) · Göteborg University (2) · Istituto Auxologico Italiano (2) · University of Michigan (2) · University of Washington (2) · Yale University (2) · 5i Sciences, Inc. (1) · American University of Beirut Medical Center (1) · ApniCure, Inc. (1)
United States (70) · Australia (7) · France (4) · Italy (4) · Canada (3) · Germany (3) · Switzerland (3) · United Kingdom (3) · Spain (2) · Sweden (2) · Belgium (1) · Brazil (1) · China (1) · Denmark (1) · Finland (1)
Scott A Sands, PhD (4) · Bradley A Edwards, PhD (3) · Carl J Stepnowsky, PhD (3) · Christopher Schmickl, MD, PhD (2) · Dawn M Bravata, MD (2) · Elisa Perger, MD (2) · Jan Hedner, MD. Prof. (2) · Jeremy Orr, MD (2) · Ron Farkas, MD (2) · Abdulghani Sankari, MD PhD (1) · Alan R Schwartz, M.D. (1) · Alexandra Kearson, BA (1) · Andrew Wellman, MD PhD (1) · Andrew Wellman, MD, PhD (1) · Anne Monique Nuyt, MD (1)
PMID 39688178, PMID 12105286, PMID 12126214, PMID 15112907, PMID 17294232, PMID 17441783, PMID 17513285, PMID 18513353, PMID 18711110, PMID 19122865, PMID 21306949, PMID 21801857, PMID 21885958, PMID 21886365, PMID 22043118, PMID 22131599, PMID 22334806, PMID 22547887, PMID 22572632, PMID 22893765, PMID 22968110, PMID 24458967, PMID 24815497, PMID 24918372, PMID 25136550, PMID 25268234, PMID 25770408, PMID 25805361, PMID 25892349, PMID 26210388, PMID 26643404, PMID 26967681, PMID 27092703, PMID 27110692, PMID 28364504, PMID 28387543, PMID 29035093, PMID 29065955, PMID 29121334, PMID 29510792, PMID 29602814, PMID 29718281, PMID 29750475, PMID 29800001, PMID 29800466, PMID 30325462, PMID 30395486, PMID 31119695, PMID 31922899, PMID 32649638
K23HL151880 (2), 1IK2CX000547 (1), 2009 (1), 2015 (1), 2017 (1), 2019 (1), R01HL065176 (1), R01HL084139 (1), R01HL106410 (1), R01HL128658 (1), R01HL146697 (1), R01NS042698 (1), R03HL138068 (1), R61HL151254 (1), U01HL105365 (1)